Moleculin Positive Data on High Anti-Cancer Activity of Annamycin and Non-Cardiotoxicity

 

Annamycin demonstrated to be a more potent inhibitor of topoisomerase II-alpha and II-beta while remaining inactive against established cardiomyocyte cultures Results clearly aligned with lack of drug-related cardiotoxic events in patients treated with Annamycin in ongoing clinical trials; 100% of Annamycin subjects in multiple studies (N=82) continue to show no signs of cardiotoxicity during study A prominent treatment for many adult cancers and approximately 50% of all pediatric cancer patients are treated with a cardiotoxic anthracycline Annamycin composition of matter patent issued April 9th; Patent enables expansion into greater patient populations where cardiotoxicity remains an unmet need https://www.biospace.com/article/releases/moleculin-announces-presentation-of-positive-data-demonstrating-high-anti-cancer-activity-of-annamycin-and-non-cardiotoxic-properties/